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Abstract
Chronic adipose tissue inflammation is a hallmark of obesity-induced insulin resistance and anti-inflammatory agents can
benefit patients with obesity-associated syndromes. Currently available type I interferons for therapeutic immunomod-
ulation are accompanied by high cytotoxicity and therefore in this study we have examined anti-inflammatory effects of
interferon tau (IFNT), a member of the type I interferon family with low cellular toxicity even at high doses. Using a diet-
induced obesity mouse model, we observed enhanced insulin sensitivity in obese mice administered IFNT compared to
control mice, which was accompanied by a significant decrease in secretion of proinflammatory cytokines and elevated anti-
inflammatory macrophages (M2) in adipose tissue. Further investigations revealed that IFNT is a potent regulator of
macrophage activation that favors anti-inflammatory responses as evidenced by activation of associated surface antigens,
production of anti-inflammatory cytokines, and activation of selective cell signaling pathways. Thus, our study
demonstrates, for the first time, that IFNT can significantly mitigate obesity-associated systemic insulin resistance and
tissue inflammation by controlling macrophage polarization, and thus IFNT can be a novel bio-therapeutic agent for
treating obesity-associated syndromes and type 2 diabetes.
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Introduction
Obesity and its associated metabolic abnormalities, including
insulin resistance and cardiovascular disorders, have reached
epidemic proportions. Chronic low degree adipose tissue inflam-
mation, accompanied by enhanced immune cell infiltration, is a
hallmark of obesity and a crucial contributor to the pathogenesis of
insulin resistance and metabolic diseases [1–7]. The infiltrated
immune cells play critical roles in modulating obesity-associated
adipose tissue inflammation. Among them, macrophages account
for up to 50% of the stromal cell population in adipose tissues of
obese individuals and are critical regulators of adipose tissue
functions [3,8–11]. In addition, adipose tissue macrophages
(ATMs) undergo a phenotypic switch from anti-inflammatory
status (M2) in the adipose tissues of lean individuals to a
proinflammatory (M1) status in adipose tissues of obese subjects,
which results in the development of tissue inflammation and
systemic insulin resistance [12,13]. The classic proinflammatory
responses of ATMs (M1) depend on Toll-Like Receptors (TLRs)
and activation of nuclear factor kB (NFkB)/c-Jun N-terminal
kinase (JNK), leading to the production of inflammatory cytokines
[14]. In contrast, activation of M2 ATM leads to recruitment of
peroxisome proliferator-activated receptor c (PPARc) or other
transcription factors resulting in an anti-inflammatory status
[13,15–17]. Our recent study revealed that other molecules, such
as microRNAs, can exhibit profound regulatory functions on
macrophage polarization [18]. It has been demonstrated that
activation of M2 macrophages can improve systemic insulin
sensitivity and protect against development of cardiovascular
diseases and type 2 diabetes [19,20].
Clinical studies show the anti-inflammatory treatments can
benefit patients with systemic insulin resistance [21–23]. Type I
interferons have been used as anti-inflammatory therapies by
suppressing production of inflammatory cytokines such as
interleukin (IL)-1b and tumor necrosis factor a (TNF-a) [24–
26].However, severe cell toxicities associated with currently
available type I IFNs, such as IFN-a and -b (IFNA and IFNB)
[27,28], dramatically hinder their clinic application. Recent
studies revealed that a member of type I IFN family, interferon
tau (IFNT), exerts potent immunomodulatory effects with very low
cytotoxicity even at high dosages, which providessupport for a
clinic application of IFNT.
IFNT is a type I interferon produced exclusively by trophec-
toderm cells of conceptuses of ruminant species and plays a central
role for successful implantation and establishment of pregnancy
[29]. IFNT shares high protein structural similarities with other
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members of the type I interferon family, such as IFNA and IFNB
and particularly interferon omega (IFNW) [30]. Compared with
IFNA and IFNB that have been applied as clinical therapeutics,
IFNT lacks their cytotoxicity even at high concentrations [31,32].
Previous studies have shown that IFNT can shift the immune
profile from an inflammatory to an anti-inflammatory phenotype
to mitigate against autoimmune-associated diseases [33,34]. Here,
we show that IFNT is a potent regulator of macrophage
polarization that significantly suppresses obesity-associated adipose
tissue inflammation and ameliorates systemic insulin resistance.
Thus, this study provides important evidence, for the first time,
toward understanding the regulatory mechanism of IFNT action
in the context of obesity and indicates potential clinical




Male C57BL/6J mice 6 weeks of age were used for diet feeding
and bone marrow isolation and macrophage activation analyses.
All mice were maintained on a 12-/12-hour light-dark cycle and
fed ad libitum. To induce obesity, mice were fed a high-fat diet
(HFD; 60% fat calories, 20% protein calories, and 20%
carbohydrate calories; Research Diets, Inc) for 12 weeks. Mice
fed on a low-fat diet (LFD; 10% fat calories, 20% protein calories,
and 70% carbohydrate calories; Research Diets, Inc) served as
controls. In the IFNT treatment, mice received recombinant
IFNT via drinking water (8 mg/kg body weight/day) for 12 weeks
[21]. The IFNT delivered orally in drinking water was detected in
plasma of mice using a highly specific and sensitive radioimmu-
noassay (FigureS1) [35]. Glucose metabolism and insulin sensitiv-
ity of LFD and HFD mice were evaluated by measuring
concentrations of glucose and insulin in plasma, andconducting
glucose tolerance and insulin tolerance tests. The glucose tolerance
and insulin tolerance tests were performed during week 12 of the
study, and there was a 6-day interval between these two tests. In
addition, the glucose tolerance and insulin tolerance tests were
performedbetween 8:00 AM and 10:00 AM for all mice. Blood
samples were collected fromthe tail vein in EDTA-coated tubes,
and plasma was harvested afterthe blood was centrifuged at
1,0006g for 15 min at 4uC. At the end of the study, all mice were
euthanized between 8:00 AM and 10:00 AM by exposure to high
dosage of carbon dioxide (CO2).In this study, we combined the
visceral adipose tissues (VAT; retroperitoneal fat, kidney fat,
gastrointestinal fat, epididymal fat) for isolation of mature
adipocytes, measurement of metabolic gene expression, immuno-
histochemistry, and evaluation of immune cell infiltration. The
VAT from mice were fixed in fresh 4% paraformaldehyde
andused for immunohistochemical analysis or snap frozen in
liquid nitrogen and stored in 280uC. All study protocols were
approved by the Institutional Animal Care and Use Committee of
Texas A&M University.
Mature adipocyte isolation and ex vivo analysis of insulin
signaling
VAT wasmincedand digested in Hank’s Balanced Salt Solution
(HBSS) digestion buffer containing 1 mg/mL of collagenase II,
1% BSA and 100 mM HEPES for 40 min at 37uC.After passing
Figure 1. Interferon tau (IFNT) alleviates high-fat diet (HFD)-induced insulin resistance. Body weight (A) and food intake (B) of mice were
monitored during a 12-week feeding period (n = 9–10). (C) Concentrations of glucose and insulin in plasma of control or IFNT-treated mice fed a HFD
or low-fat diet (LFD), or fasted for 16 h. (D) Glucose tolerance test (n = 6). (E) Insulin tolerance test (n = 6). Data are presented as mean 6 SEM. *P,
0.05, **P,0.001, ***P,0.0001.
doi:10.1371/journal.pone.0098835.g001
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through a 250 mm nylon mesh,the stromal cells and mature
adipocytes were separated by centrifuging at 1,5006g for 5 min at
4uC.For ex vivo analysis of insulin signaling, the mature adipocytes
were collected and stimulated with or without 100 nM insulin in
Dulbecco’s Modified Eagle Medium/Nutrient F-12 Ham
(DMEM/F12)for 15 min, followed by cell lysis in Radio-Immu-
noprecipitation Assay (RIPA) buffer containinga protease/phos-
phatase inhibitor cocktail.
Bone marrow isolation and macrophage differentiation
Bone marrow-derived macrophages (BMDMs) were obtained as
described previously [36]. After red blood cell lysis, bone marrow
cells were seeded at 26106 cells/mL with Iscove’s Modified
Dulbecco’s Medium (IMDM) medium containing 10% FBS and
15% L929 culture supernatant as a source of granulocyte
macrophage colony-stimulating factor(GM-CSF) for differentia-
tion of bone marrow cells to monocytes. After 7 days, the
formation of mature monocytes was evaluated by flow cytometry
using antibodies against CD11b and F4/80.
Macrophage polarization analysis
BMDMs were stimulated by lipopolysaccharide (LPS; 100 ng/
mL) for M1 activation or IL-4 (20 ng/mL) for M2 activation. To
test the dosage effects of IFNT, BMDMs were treated with IFNT
at 10,000, 5,000, or 1,000 anti-viral units (AVU)/mL for 48 h with
LPS or IL-4 (FigureS2). After 48 h of stimulation, BMDMs were
examined for activation of expression of associated surface
antigens CD69, CD80, and CD86 using flow cytometry.
Flow cytometry analysis
Unless specified, antibodies were obtained from eBioscience.
Vascular stromal cells (VSC) of VAT and BMDMs were stained
with fluorescence-conjugated antibodies to detect cell lineages in
VAT or their activation. B cells were detected with antibodies
against B220, CD19, CD5 and CD43; T cells were detected with
antibodies against CD4 and CD8; macrophage subtypes and
activation of macrophages were detected using antibodies against
F4/80, CD11b, CD206 (Biolegend), CD11c, CD80, CD86, and
CD69. Phosphorylated signal transducers and activators of
transcription 1 (STAT1) and STAT3 of BMDMs were detected
using an intracellular staining assay. Flow cytometry analysis was
performed using Accuri C6 (BD Bioscience), and results were
analyzed using Flowjo or Accuri C6 software (BD Bioscience).
Immunohistochemistry
Tissues collected from HFD-fed mice were fixed andstained
with antibodies against F4/80, B220, and CD3 (eBioscience) to
detect macrophages, B cells, and T cells, respectively. Immuno-
Figure 2. IFNT reduces obesity-associated adipose tissue inflammation. (A) Visceral adipose tissues (VAT) weight and adiposity of mice after
12-week HFD feeding. (B) Nuclear factor-kB (NFkB) activation in VAT of HFD mice. Western blotting was performed with antibodies against p65 and
phosphorylated p65 (Pp65; n = 3). C, control; T, IFNT. (C) Activation of c-Jun N-terminal kinase (JNK) signaling pathway in VAT of HFD mice.
Fluorescent-labeled beads conjugated with antibodies against total JNK (tJNK) and phosphorylated JNK (phospho JNK) in VAT were measured using
the Bio-PlexH MAGPIXTM multiplex reader. MFI, medium fluorescence intensity. Data are presented as mean 6 SEM. *P,0.05.
doi:10.1371/journal.pone.0098835.g002
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globulin (IgG) protein was used as the negative control. Images
were captured using a Zeiss Stallion Dual Detector Imaging
System with Intelligent Imaging Innovations Software (Carl Zeiss).
Western blotting
After homogenization of VATs using the BeadBugTMmicrotube
homogenizer (Benchmark Scientific),total protein was extracted
from VAT homogenate using a RIPA buffer, and protein
concentrations were determined using the Bradford assay. Proteins
were separated on PROTEANH TGX Stain-FreeTM Precast Gel
(Bio-Rad) and transferred onto a polyvinylidene fluoride (PVDF)
membrane followed by detection using antibodies directed against
the respective antigens. Activation of NFkB pathway in adipose
tissues was evaluated using antibodies against p65 and phosphor-
ylated p65 (Pp65; Cell Signaling TechnologyH).
Quantitative reverse transcriptase-polymerase chain
reaction (qRT-PCR) analysis
Total RNA was extracted from adipose tissues or BMDMs using
the Trizol extraction protocol according to the manufacturer’s
instructions. Gene expression analysis was performed using a
iScript One-Step RT-PCR kit with SYBR Green (Bio-Rad) on
Bio-Rad CFX384 (Bio-Rad). The data presented correspond to
the mean of 22DDCt from at least three independent experiments-
after being normalized to b-actin.
Bio-Plex protein expression assay
The concentrations of IL-1b, TNF-a, IL-6, IL-10, and
chemokine (C-C motif) ligand 2 (CCL2) in plasma were
determined using Bio-PlexTMCytokine Assay (Bio-Rad). Concen-
trations of insulin in plasma were determined using the Bio-Plex
Pro Mouse Diabetes Insulin set (Bio-Rad). The levels of total and
phosphorylated JNK, and total and phosphorylated Akt in mature
adipocytes were determined using the Bio-Plex Cell Signaling
Magnetic Assays (Bio-Rad). These Bio-Plex assays were performed
using the Bio-Plex MAGPIXTM multiplex reader (Bio-Rad).
Results were analyzed using Bio-Plex Data ProTM software (Bio-
Rad).
Data and statistical analyses
Results are expressed as means 6 SEM. Each data point
derived from qRT-PCR assays represents an average of two
Figure 3. IFNT administration altered the cytokine profile and insulin signaling. (A) Gene expression of cytokines. Cytokines, chemokine
(C-C motif) ligand 2 (CCL2) and adipokineadiponectin in VAT of HFD mice measured using quantitative reverse transcriptase-PCR (qRT-PCR;
normalized to b-actin). IL, interleukin; TNF-a, tumor necrosis factor-a. (B) Concentration of IL-1b, IL-6, TNF-a, CCL2, and IL-10 in plasma of HFD mice
were measured using the Bio-PlexTMCytokine Assay (Bio-Rad). (C) Adipose tissue insulin signaling. After 16-h fasting, mature adipocytes were
collected from VAT and treated with insulin (100 nM) for 15 min. Total AKT (tAKT) and phosphorylated AKT (pAKT) protein in adipocytes were
measured using Bio-Plex Cell Signaling Magnetic Assays (Bio-Rad). Data are presented as mean 6 SEM. *P,0.05.
doi:10.1371/journal.pone.0098835.g003
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technical replicates, and data were averaged over independently
replicated experiments (n = 3–4 independently collected samples)
and analyzed using the Student’st test. The overall group-effect
was analyzed for significance using two-way ANOVA and
Bonferroni post-test for each factor at each individual time. Data
analyses were performed using Graphpad Prism version 6.0
software. A value of P,0.05 was considered statistically significant.
Results
Interferon tau alleviates obesity-induced insulin
resistance
To evaluate the effects of IFNT on obesity-associated inflam-
mation and insulin resistance, we adopted a dietary-induced
obesity model. An effective IFNT dose was chosen based on
previous studies [37]. After 12 weeks feeding, IFNT treatment did
not significantly affect body weight gain or food intake in either
HFD or LFD groups (Figure 1A, B). However, compared to the
control HFD mice (HFD-Control mice), IFNT treatment (HFD-
IFNT mice) decreased hyperglycemiaand blood insulin levels
(Figure 1C). In addition, HFD-IFNT mice had lower glucose and
insulin levels after 16-h of fasting compared to the HFD-Control
mice (Figure 1C). To evaluate the effects of IFNT on insulin
sensitivity, mice were subjected to glucose and insulin tolerance
tests. Mice were fasted for 16 h and then injected with a single
dose of glucose (2 mg of glucose per gram of body weight) or
insulin (1 U of insulin per kg of body weight) followed by
determination of concentrations of blood glucose at various time
points (Figure 1D, E). With LFD mice, IFNT treatment did not
alter concentrations of glucose or insulin in plasma; whereas HFD-
IFNT mice had lower concentrations of glucose than HFD-
Control mice (Figure 1D, E). Collectively, these results suggest that
IFNT improves obesity-associated glucose metabolismand insulin
sensitivity.
Interferon tau alleviates obesity-associated inflammation
There is compelling evidencefor causal effects of obesity-
associated chronic inflammation, especially in adipose tissues of
obese individuals, and the pathogenesis of systemic insulin
resistance [1]. Although HFD-IFNT and HFD-Control mice
had similar degrees of adiposity (Figure 2A), IFNT treatment
suppressed activation of NFkBactivation as evidenced by lower
p65 phosphorylation and JNK pathway activity as evidenced by
decreased phosphorylated-JNK in VAT of HFD mice (Figure 2B,
C). In addition, HFD-IFNT mice displayed lower levels of
proinflammatory cytokines, namely IL-1b, IL-6 and TNF-a, and
Figure 4. IFNT regulates macrophage activation in adipose tissues of mice fed a HFD. (A) Adipose tissue sections of HFD mice were
stained with antibodies against F4/80, B220 and CD3 for macrophages, B cells and T cells, respectively. (B) Macrophage (M), B cell (B), CD4+ T cell (T4)
and CD8+ T cell (T8) infiltration in VAT of HFD-fed mice was analyzed by flow cytometry with antibodies against F4/80, CD11b, B220, CD4 and CD8. (C)
Macrophage subtypes in visceral fat stromal cells (VSC) of VAT were analyzed by flow cytometry using antibodies against F4/80, CD11b, CD11c and
CD206. Data are presented as mean 6 SEM. *P,0.05, **P,0.001, ***P,0.0001.
doi:10.1371/journal.pone.0098835.g004
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increased expression of the anti-inflammatory cytokine IL-10 in
adipose tissuecompared to HFD-Control mice (Figure 3A).
However, the expressionof CCL-2 in adipose tissues isolated from
HFD mice was not affected by IFNT treatment (Figure 3A).
Expression of adiponectin, an adipokine negatively associated with
obesity, was induced by IFNT treatment in HFD mice compared
to the control group (Figure3A). We also detected decreasedcon-
centrations ofCCL2 and TNF-a and elevated concentration of IL-
10 in plasma of HFD-IFNT mice compared to HFD-Control mice
(Figure 3B). We further determined the impact of IFNT treatment
on the insulin signaling pathway in adipose tissues of HFD mice.
In the ex vivoanalysis of insulin signaling, we detected an increase in
the abundance of phosphorylated Akt protein in isolated mature
adipocytes treated with insulin compared to that in mature
adipocytes from mice that were not treated with insulin. This
result indicates that insulin successfully activated the intracellular
insulin signaling pathway in the isolated mature adipocytes.Inter-
estingly, total Akt protein and its insulin-responsive phosphoryla-
tion were both greater in mature adipocytes isolated from HFD-
IFNT mice than HFD-Control mice (Figure 3C).Taken together,
our results suggest that IFNT treatment effectively modulates
obesity-associated insulin resistance at least by suppressing tissue
inflammation.
Interferon tau regulates macrophage activation in
adipose tissues of HFD mice
To further understand the impact of IFNT on adipose tissue
immune cell populations that are major contributors to adipose
tissue inflammatory status [4-6,13], we examined the relative
proportions of T cells, B cells and macrophages in visceral stromal
cells of VAT from HFD-IFNT and HFD-Control mice. We first
performed immunohistochemical staining on visceral adipose
tissues isolated from both HFD-IFNT and HFD-Control groups
with antibodies against F4/80 (macrophages), B220 (B cells) and
CD3 (T cells). The results indicated that total numbers of
macrophages, B cells and T cells infiltrated into VAT are
comparable in HFD-IFNT mice and HFD-Control mice
(Figure 4A). This was confirmed by further analysis using flow
cytometry assays with the same set of antibodies. Consistent with
results of immunohistochemical staining, the proportions of total
macrophages (F4/80+CD11b+), B cells (B220+) and T cells (CD4+
or CD8+) were not significantly different between IFNT treated
and control mice on either HFD (Figure4B) and LFD (FigureS3).
Figure 5. IFNT modulates macrophage polarization and cytokine profiles. The surface makers CD69, CD80, and CD86 of BMDMs were
analyzed using flow cytometry after 48-hIL-4 (20 ng/mL; A) or lipopolysaccharide (LPS, 100 ng/mL; B) stimulation (n = 3). BMDMs were treated with
IFNT at 5,000 antiviral units (AVU)/mL. The expression of cytokines IL-1b (C), TNF-a (D) and IL-10 (E) and peroxisome proliferator-activated receptor c
(PPARc) (F) in BMDMs activated in the presence of IFNT (black bars) were analyzed by qRT-PCR (normalized to b-actin, n = 3) and compared to
activated BMDMs with no IFNT treatment (white bars). Data are presented as mean 6 SEM. *P,0.05, **P,0.001, ***P,0.0001. MFI, medium
fluorescence intensity.
doi:10.1371/journal.pone.0098835.g005
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Surprisingly, the distribution of macrophage subpopulations, i.e.
M1 and M2 macrophages, was significantly altered by IFNT
treatment. Compared to the HFD-Control mice, HFD-IFNT mice
displayed dramatically decreasedproinflammatory M1 macro-
phages (F4/80+CD11b+CD206-CD11c+; Figure 4C)and a signif-
icant increase in anti-inflammatory M2 macrophages (F4/
80+CD11b+CD206+CD11c-; Figure4C) which suggests a regula-
tory role for IFNT in macrophage polarization.
Interferon tau modulates macrophage polarization
Given the distinct shift in activation status of adipose tissue
macrophages in vivo, we further evaluated the effects of IFNT on
macrophage polarization using a well-established in vitro model
[36].Bone marrow-derived macrophages were treated with IFNT
at various dosage in the presence of LPS (100 ng/mL) for M1
activation or IL-4 (20 ng/mL) for M2 activation and activation of
associated surface antigens was determined using flow cytometry
assays. M2 macrophages (IL-4 treatment) displayed a significantly
enhanced activation pattern as judged by stronger induction of
surface markers CD69, CD80, and CD86 at 48 h after stimulation
(Figure 5A). In contrast, activation of M1 macrophages induced by
LPS treatment was significantly stalled in the presence of IFNT
resulting in the left shift of surface marker levels (Figure 5B). We
further examined the cytokine production profiles in these M1 and
M2 macrophages using qRT-PCRanalysis. As expected, IFNT-
significantly suppressed expression of proinflammatory cytokines
IL-1b and TNF-a by BMDMs in response to LPS stimulation
compared to control BMDMs (Figure5C, D). In addition, cells also
displayed a slight increase in IL-10 upon IL-4 stimulation in the
presence of IFNT (Figure5E). PPARc is a key regulator that
suppresses proinflammatory M1 and promotes anti-inflammatory
M2 activation. Interestingly, IFNT did not affect IL-4-dependent
PPARcexpression in M2 macrophages, but IFNT significantly
increased PPARc expressionin M1 macrophages (Figure 5F),
which suggests a potent inflammatory suppressing impact of IFNT
on macrophage polarization.
To understand the mechanism of IFNT action in regulating
macrophage polarization, we examined signaling pathways
mediated by type I interferon receptors in activated macrophages.
We found that the expression of type I interferon receptor
(IFNAR) was not affected by IFNT treatment in activated
BMDMs (FigureS4). However, IFNT significantly enhanced
STAT3 activation upon IL-4 stimulation as evidenced by
significantly elevated phosphorylated STAT3 proteindetected by
intracellular staining assays followed by flow cytometry analysis
(Figure6A). Alternatively, type I interferons can exert anti-
inflammatory functions through inducing activation of interfer-
on-stimulated gene factor-3 (ISGF3) complex, which includes
STAT1, STAT2, and interferon regulatory factor 9 (IRF9). In M2
macrophages, activation of STAT1 was increased by IFNT
compared to the control (Figure6B).In LPS-stimulated BMDMs,
IFNT did not affect the phosphorylation status of STAT1 or
STAT3 (Figure6A, B). In addition, the abundance of IRF9 was
significantly decreased in M1 macrophages, but increased in M2
macrophages in response to IFNT (Figure6C). Thus, these results
suggest that IFNT may modulate macrophage polarization
primarily through controlling activation of ISGF3 complex and
STAT3 pathway.
Discussion
Adipose tissue inflammation is a major contributor to the
pathogenesis of obesity-associated insulin resistance [1–7].Using a
diet-induced obesity model, we observed a significant increase in
inflammation at both adipose tissue and systemic circulation levels
in obese mice, accompanied by exacerbated insulin resistance.
This is consistent with previous reports and confirms the direct
correlation of tissue inflammation with obesity-associated insulin
resistance [1–7]. Thus, our research provided a new set of
evidences to support the development of therapeutic strategy with
anti-inflammatory agents to treat patients with obesity-induced
insulin resistance and subsequent type 2 diabetes. Type I
interferons exert profound anti-inflammatory effects through
Figure 6. IFNT induces STAT1 and STAT3 activation in BMDMs. (A) The phosphorylation of signal transducer and activator of transcription 3
(pSTAT3) and (B) pSTAT1 in BMDMs was measured by flow cytometry after 90-min of LPS (100 ng/mL) or IL-4 (20 ng/mL) stimulation (n = 3). (C) The
expression of interferon regulatory factor 9 (IRF9) was analyzed by qRT-PCR after 48-h LPS (100 ng/mL) or IL4 stimulation (20 ng/mL); n = 3. Data are
presented as mean 6 SEM. *P,0.05, **P,0.001.
doi:10.1371/journal.pone.0098835.g006
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modulating immune cell functions [24]. However, patients treated
with IFNA and IFNB, two of the available options in this category,
often display severe high fever, as well as damage to liver and
kidney functions [27,28,38].Such severe adverse effects greatly stall
the beneficial expectation of their applications. Compared to
IFNA and IFNB, IFNT displays similar immunomodulatoryfunc-
tions but low cytotoxicity even at higher dose, thus can provide a
new option to treat obesity-induced insulin resistance and
autoimmune disorders [31,33].
Type I interferons share high similarities among their members
in both primarynucleotide coding and protein folding structure
[30]. Structural analysis demonstrates that IFNT binds to type I
interferon receptors to activatetype I interferon intracellular
signaling pathways that alter immune status [39].This is confirmed
in our study using an in vitro culture system. IFNT-treated BMDMs
displayed a significantly suppressed inflammatory response to
LPSaccompanied by decreased production of IL-1b and TNF-a.
This effect is partially mediated by suppressingthe ISGF3 pathway.
In addition, IFNT significantly enhanced the anti-inflammatory
response, namely activation of M2 macrophages. Accordingly,
decreased expression of IL-1b was observed in BMDMs stimulated
with IL-4 in the presence of IFNT. Our in vivo results further
confirmed the anti-inflammatory effects of IFNT in adipose
tissues, evidenced by suppression on inflammatory pathwaysand
production of proinflammatory cytokines.
Given the potent anti-inflammatory effects of IFNT in vivo, it is
not surprising that IFNT ameliorated insulin resistance in the
obese mice. IFNT administration did not affect body weight gain
or adiposity of obese mice, or metabolic status of adipose tissues
and liver of obese mice (Figure S5), but there was a decrease in
concentration of triglycerides in plasma from HFD-IFNT mice
(Figure S6). These results are not consistent with results of a
previous study withZucker diabetic fatty rats [37].This may be due
to differences in animal models and length of IFNT treatment of
the rats to 12 weeks of age. Intriguingly, the composition of
infiltrated immune cells, especially the macrophage subtypes, in
the adipose tissueswas significantly altered upon IFNT treatment.
The overall adipose tissue immune cells including T cell, B cell and
macrophage populations in the mice treated with IFNT were
comparable to the control mice, suggesting that IFNT treatment
did not affect immune cell recruitment, which was concomitant
with unchanged expression of CCL2in adipose tissuesfrom IFNT-
treated HFD mice and control mice. However, adipose tissue
inflammation was significantly suppressed by IFNT treatment as
evidenced by decreased proinflammatory cytokine expression
levels, which was associated with elevated Akt activation upon
insulin stimulation. This is partially attributed to the shift of
adipose tissue macrophage status distribution resulting in more M2
than M1 macrophages. The M2 macrophages exert anti-
inflammatory effects in the tissue microenvironment including
regulation through increasing secretion of anti-inflammatory
cytokines, including IL-10 [13]. We observed greater abundance
of IL-10 in HFD mice treated with IFNT. Results of a previous
study suggest that type I interferons act through either the ISGF3
complexity or STAT3 in immune cells [24,25]. Our results
suggested that IFNT may function through the ISGF3 complexin
macrophages and also exerts a significant impact on STAT3
phosphorylation, resulting in significantly enhanced production of
IL-10. Further understanding the mechanism of IFNT action in
mitigating obesity-associated symptoms and its potential impact on
other immune cell activation await further investigations.
In summary, results of our study demonstrate that IFNT is a
potent regulator for obesity-associated insulin resistance and tissue
inflammation that is accounted for partially by effects of IFNT to
control adipose tissue macrophage polarization. Given its low
cytotoxicity compared to other members of the type I interferon
family, our study provides the first evidence to support the
potential application of IFNT to mitigate obesity-associated
syndromes including various autoimmune diseases.
Supporting Information
Figure S1 Concentrations of interferon tau (IFNT) in
plasma of HFD-fed mice were determine by radioim-
munoassay (n=4–5). Data are presented as mean 6 SEM.
(TIF)
Figure S2 Dosage effect of IFNT on macrophage
polarization. Bone marrow-derived macrophages (BMDMs)
were stimulated with LPS (100 ng/mL) or IL4 (20 ng/mL). In
addition, BMDMs were treated with IFNT at 1,000(T1),
5,000(T2), 10,000(T3), or 0 anti-viral unit (AVU)/mL (n= 3).
After 48 hours, the surface makers CD69, CD80, and CD86 of
BMDMs by were analyzed using flow cytometry. Data are
presented as mean 6 SEM. *P,0.05, **P,0.001.
(TIF)
Figure S3 The infiltration of immune cells in adipose
tissues of LFD mice. A: Macrophage (M), B cells (B), CD4+ T
cells (T4) and CD8+ T cells (T8) in visceral fat stromal cells (VSC)
of visceral adipose tissues (VATs) of LFD mice were analyzed by
flow cytometry using antibodies against F4/80, CD11b, B220,
CD4 and CD8 (n = 3–4). B: Macrophage subtypes in VSC of
VATs of LFD mice were analyzed by flow cytometry using
antibodies against F4/80, CD11b, CD11c and CD206 (n= 3–4).
Data are presented as mean 6 SEM.
(TIF)
Figure S4 Effect of IFNT on the expression of type I
interferon receptor in BMDMs. The abundance of type I
interferon receptor in BMDMs was analyzed by qRT-PCR after
48-hours stimulation with LPS (100 ng/mL) or IL4 (20 ng/mL;
n= 3). For the IFNT treatment, BMDMs were treated with IFNT
at 5,000 AVU/mL. Data are presented as mean 6 SEM.
(TIF)
Figure S5 The expression of key regulators for lipogen-
esis, mitochondrial function, lipolysis was measured in
the adipose tissues (A) and liver (B) collected from HFD
mice or HFD-IFNT mice using qRT-PCR (normalized to
b-actin). Data are means 6 SEM, n=3. ACC, acetyl-CoA
carboxylase; FAS, fatty acid synthetase; SCD1, stearoyl-CoA
desaturase-1; PGC1b, peroxisome proliferator-activated receptor
gamma, coactivator 1 beta; CPT1, carnitinepalmitoyltransferase
1; HSL, hormone-sensitive lipase; G6pase, glucose 6-phosphatase;
PEPCK, phosphoenolpyruvatecarboxykinase.
(TIF)
Figure S6 Concentration of triglyceride in plasma of
control or IFNT-treated mice fed a HFD diet or fasted
for 16 h. Data are presented as mean 6 SEM.
(TIF)
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